11 October 2019


Geert Kops receives ERC Synergy Grant

Elize Brolsma

Oncode's Scientific Director Geert Kops (Hubrecht Institute) has received a European Research Council (ERC) Synergy Grant to investigate the causes and effects of chromosomal aberrations in cancer, together with Iva Tolic (Ruder Boskovic Institute), Angelika Amon (Massachusetts Institute of Technology) and Nenad Pavin (University of Zagreb). Together they receive 10 million euros for their interdisciplinary effort that combines cell biology, bio(physics) and genetics.

Chromosomal aberrations are prevalent during early embryonic development and in cancer, but it is unclear how these aberrations originate and how these aberrations exactly affect early embryonic and cancer development. The results of this research will help to elucidate these questions. In addition, the researchers will develop new methods to perform quantitative cell biology in human tissues. At the moment cellular processes are mainly studied in mono-layer cell lines due to the challenging nature of human 3D tissue. Studying cellular processes in human tissue will greatly expand our knowledge on how cells function in their native environment.

Geert Kops says: "This European Synergy grant provides a unique opportunity for us to work with teams from different disciplines including physics and genetics to discover the origins of chromosome aberrations in cancer. Our contribution will focus on studying molecular processes in human cancer organoids."

Other News

Founding Principles Card@2X
New vacancies at Oncode Partner Institutes
Are you planning on the next steps in your scientific career? Check out the latest vacancies at the labs of Oncode Investigators.
About Card
Researchers explain the added value of Oncode Institute
At this year's Oncode-CGC Annual conference, we took the time to speak with some of our Oncode Investigators. In this video, they explain the value that Oncode adds to their research, collaboration opportinuties and valorization success.
Oncode Institute invests 4 million euros in new technology for cancer research in the Netherlands
Oncode Institute invests 4 million euros in unique, state-of-the-art technology for cancer research. Five projects have been awarded within the Infrastructure & Technologies Programme. These technologies will not only become available for the twelve institutes that are affiliated with Oncode Institute but will also be made available to the wider research community in the Netherlands.